StoxNarayana Hrudayalaya vs Dr. Lal Path Labs: share price & financials comparison
NSE: NH vs LALPATHLAB · Healthcare · as of 13 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Narayana Hrudayalaya vs Dr. Lal Path Labs at a glance
Narayana Hrudayalaya (NH) has a market capitalisation of ₹38,019 Cr, against ₹33,443 Cr for Dr. Lal Path Labs (LALPATHLAB). Over the past year Dr. Lal Path Labs has returned +26.4%, compared with +1.6% for Narayana Hrudayalaya. On valuation, Narayana Hrudayalaya trades at a lower P/E of 44.3 versus 57.3. Dr. Lal Path Labs earns a higher return on equity (21.3% vs 17.2%). Narayana Hrudayalaya comes out ahead on size, valuation, growth and momentum. Dr. Lal Path Labs comes out ahead on profitability and technicals. Across the scored metrics below, Narayana Hrudayalaya leads on 9 and Dr. Lal Path Labs on 8. On StoxGud's 10-point checklist, Narayana Hrudayalaya scores 7/10 and Dr. Lal Path Labs scores 9/10.
| Metric | Narayana Hrudayalaya | Dr. Lal Path Labs |
|---|---|---|
| Size | ||
| Market cap | ₹38,019 Cr | ₹33,443 Cr |
| Revenue (latest FY) | ₹7,896 Cr | ₹2,763 Cr |
| Net profit (latest FY) | ₹806 Cr | ₹505 Cr |
| Valuation | ||
| P/E | 44.3 | 57.3 |
| P/B | 7.60 | 12.19 |
| Dividend yield | 0.24% | 0.67% |
| Profitability | ||
| Return on equity | 17.2% | 21.3% |
| Net profit margin | 8.4% | 19.2% |
| Operating margin | 18.5% | 29.5% |
| Growth | ||
| Revenue growth (YoY) | +73.0% | +19.6% |
| Net profit growth (YoY) | +16.5% | +27.6% |
| Revenue CAGR (multi-year) | +25.0% | +11.8% |
| Financial health | ||
| Debt to equity | 0.99 | 0.00 |
| Momentum | ||
| 1-month return | +10.3% | +4.3% |
| 1-year return | +1.6% | +26.4% |
| 3-year CAGR | +19.7% | +15.0% |
| 5-year CAGR | +27.1% | +1.7% |
| 10-year CAGR | +18.9% | +13.7% |
| Distance from 52W high | -10.6% | -1.8% |
| Technicals | ||
| RSI (14) | 76 | 68 |
| Price vs 200-day avg | +1.3% | +19.8% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Narayana Hrudayalaya | Dr. Lal Path Labs |
|---|---|---|
| Price above 50-day average | ✓ | ✓ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✗ | ✓ |
| RSI in healthy 40–70 zone | ✗ | ✓ |
| Positive 1-year return | ✓ | ✓ |
| Return on equity above 15% | ✓ | ✓ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✗ | ✓ |
| P/E below industry median | ✓ | ✗ |
| Score | 7/10 | 9/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Narayana Hrudayalaya or Dr. Lal Path Labs?
Narayana Hrudayalaya has a market cap of ₹38,019 Cr and Dr. Lal Path Labs has a market cap of ₹33,443 Cr as of 13 Nov 2026.
Which has a lower P/E, Narayana Hrudayalaya or Dr. Lal Path Labs?
Narayana Hrudayalaya has the lower P/E: Narayana Hrudayalaya trades at 44.3 and Dr. Lal Path Labs at 57.3.
Which gave better returns in the last year, Narayana Hrudayalaya or Dr. Lal Path Labs?
Dr. Lal Path Labs did better: Narayana Hrudayalaya returned +1.6% and Dr. Lal Path Labs returned +26.4% over one year.
What is the difference between Narayana Hrudayalaya and Dr. Lal Path Labs?
Both are NSE-listed companies in Healthcare. They are about the same size by market cap (₹38,019 Cr vs ₹33,443 Cr). In the latest financial year Narayana Hrudayalaya reported revenue of ₹7,896 Cr and Dr. Lal Path Labs ₹2,763 Cr. Operating margin is 18.5% for Narayana Hrudayalaya and 29.5% for Dr. Lal Path Labs. Debt to equity is 0.99 for Narayana Hrudayalaya and 0.00 for Dr. Lal Path Labs.
Which is better, Narayana Hrudayalaya or Dr. Lal Path Labs?
It depends on what you are looking for, and StoxGud does not recommend either stock. On the metrics compared above, Narayana Hrudayalaya leads on 9 and Dr. Lal Path Labs on 8. Narayana Hrudayalaya is ahead on size, valuation, growth and momentum. Dr. Lal Path Labs is ahead on profitability and technicals. On StoxGud's rules-based checklist Narayana Hrudayalaya scores 7/10 and Dr. Lal Path Labs scores 9/10. This is information, not advice: consult a SEBI-registered adviser before investing.